|
- Moderna says mRNA flu vaccine sailed through trial, beating . . .
An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a standard flu shot, the company announced this week Moderna noted that the
- Moderna Announces Positive Phase 3 Results for Seasonal . . .
mRNA-1010 demonstrated superior relative vaccine efficacy that was 26 6% (95% CI; 16 7%, 35 4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older
- Modernas flu vaccine shows positive trial results, paving . . .
Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial The positive data pave the way for
- Modernas flu shot more effective for older adults - The Hill
Moderna Inc said Monday its experimental flu shot showed positive results in a late-stage trial In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent
- Moderna announces promising efficacy results from mRNA flu . . .
Moderna today reported promising relative vaccine efficacy (rVE) findings from a phase 3 trial of its seasonal mRNA flu vaccine candidate compared to a standard-dose licensed flu vaccine in adults ages 50 years and older In a press release, the company said its candidate flu vaccine, called mRNA
- Modernas new flu shot shows strong results in older adults
Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial, the company announced Monday
- Modernas mRNA Flu Vaccine Achieves 90% Efficacy
In a landmark update that may redefine vaccine manufacturing strategies, Moderna announced on February 10, 2025, that its mRNA-based seasonal flu vaccine demonstrated a 90% efficacy rate in its Phase 3 trials—substantially outperforming traditional egg-based influenza vaccines
|
|
|